Spartan Planning & Wealth Management Purchases New Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Spartan Planning & Wealth Management purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 109 shares of the company’s stock, valued at approximately $60,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Valley National Advisers Inc. increased its stake in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares during the period. Geo Capital Gestora de Recursos Ltd acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $28,000. Covestor Ltd increased its stake in shares of IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after buying an additional 28 shares during the period. DSM Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $33,000. Finally, Venturi Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 226.3% in the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after buying an additional 43 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.18% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 0.1 %

NASDAQ:IDXX opened at $504.33 on Tuesday. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The stock has a market cap of $41.65 billion, a price-to-earnings ratio of 48.82, a PEG ratio of 4.11 and a beta of 1.33. The stock has a 50-day moving average price of $501.32 and a two-hundred day moving average price of $528.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. The company had revenue of $964.10 million during the quarter, compared to analysts’ expectations of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IDXX. Barclays decreased their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Morgan Stanley decreased their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $580.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.